Black Diamond Therapeutics (BDTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.72, -1.15% vs the prior close of $1.74.
- Volume 539.75K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BDTX dips 1.1% to $1.72. Closed at $1.72, -1.15% vs the prior close of $1.74. Day range $1.67–$1.75, opened at $1.75.
BDTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BDTX dips 1.1% to $1.72
- Closed at $1.72, -1.15% vs the prior close of $1.74. Day range $1.67–$1.75, opened at $1.75.
- Volume was 539.75K shares, 0.9x its 50-day average of 608.42K.
- Price is -13.3% vs its 50-day average ($1.98) and -22.9% vs its 200-day average ($2.23).
- 52-week range $1.60–$4.94; today's close sits at 4% of that range, 65.2% below the 52-week high.
Oct 15, 2026 — BDTX rises 2.4% to $1.74
- Closed at $1.74, +2.35% vs the prior close of $1.70. Day range $1.67–$1.74, opened at $1.69.
- Volume was 624.70K shares, 1.0x its 50-day average of 603.61K.
- Price is -12.5% vs its 50-day average ($1.99) and -22.1% vs its 200-day average ($2.23).
- 52-week range $1.60–$4.94; today's close sits at 4% of that range, 64.8% below the 52-week high.
Oct 14, 2026 — BDTX rises 1.2% to $1.70
- Closed at $1.70, +1.19% vs the prior close of $1.68. Day range $1.63–$1.76, opened at $1.67.
- Volume was 1.07M shares, 1.8x its 50-day average of 600.56K.
- Price is -14.6% vs its 50-day average ($1.99) and -24.0% vs its 200-day average ($2.24).
- 52-week range $1.60–$4.94; today's close sits at 3% of that range, 65.6% below the 52-week high.
Oct 13, 2026 — BDTX slides 5.1% to $1.68, a 1-month low on 1.9x normal volume
- Closed at $1.68, -5.08% vs the prior close of $1.77. Day range $1.60–$1.77, opened at $1.76.
- Volume was 1.14M shares, 1.9x its 50-day average of 586.33K — unusually heavy trading.
- Price is -15.6% vs its 50-day average ($1.99) and -25.1% vs its 200-day average ($2.24).
- 52-week range $1.60–$4.94; today's close sits at 2% of that range, 66.0% below the 52-week high.
Oct 12, 2026 — BDTX slides 3.3% to $1.77, a 1-month low
- Closed at $1.77, -3.28% vs the prior close of $1.83. Day range $1.76–$1.87, opened at $1.87.
- Volume was 377.70K shares, 0.6x its 50-day average of 591.23K.
- Price is -11.2% vs its 50-day average ($1.99) and -21.2% vs its 200-day average ($2.25).
- 52-week range $1.60–$4.94; today's close sits at 5% of that range, 64.2% below the 52-week high.
Oct 9, 2026 — BDTX rises 1.1% to $1.83
- Closed at $1.83, +1.10% vs the prior close of $1.81. Day range $1.79–$1.83, opened at $1.81.
- Volume was 448.80K shares, 0.8x its 50-day average of 592.98K.
- Price is -8.1% vs its 50-day average ($1.99) and -18.7% vs its 200-day average ($2.25).
- 52-week range $1.60–$4.94; today's close sits at 7% of that range, 63.0% below the 52-week high.
Oct 8, 2026 — BDTX dips 1.1% to $1.81
- Closed at $1.81, -1.09% vs the prior close of $1.83. Day range $1.77–$1.81, opened at $1.81.
- Volume was 785.00K shares, 1.3x its 50-day average of 594.67K.
- Price is -9.0% vs its 50-day average ($1.99) and -19.7% vs its 200-day average ($2.25).
- 52-week range $1.60–$4.94; today's close sits at 6% of that range, 63.4% below the 52-week high.
Oct 7, 2026 — BDTX rises 1.7% to $1.83
- Closed at $1.83, +1.67% vs the prior close of $1.80. Day range $1.77–$1.87, opened at $1.79.
- Volume was 563.30K shares, 0.9x its 50-day average of 604.59K.
- Price is -7.8% vs its 50-day average ($1.99) and -19.0% vs its 200-day average ($2.26).
- 52-week range $1.60–$4.94; today's close sits at 7% of that range, 63.0% below the 52-week high.
Oct 6, 2026 — BDTX slides 7.2% to $1.80, a 1-month low
- Closed at $1.80, -7.22% vs the prior close of $1.94. Day range $1.79–$1.96, opened at $1.94.
- Volume was 839.10K shares, 1.4x its 50-day average of 600.31K.
- Price is -9.3% vs its 50-day average ($1.98) and -20.4% vs its 200-day average ($2.26).
- 52-week range $1.60–$4.94; today's close sits at 6% of that range, 63.6% below the 52-week high.
Oct 5, 2026 — BDTX rises 2.6% to $1.94
- Closed at $1.94, +2.65% vs the prior close of $1.89. Day range $1.88–$1.95, opened at $1.90.
- Volume was 838.60K shares, 1.4x its 50-day average of 596.00K.
- Price is -2.1% vs its 50-day average ($1.98) and -14.4% vs its 200-day average ($2.27).
- 52-week range $1.60–$4.94; today's close sits at 10% of that range, 60.7% below the 52-week high.
Oct 2, 2026 — BDTX rises 0.5% to $1.89
- Closed at $1.89, +0.53% vs the prior close of $1.88. Day range $1.88–$1.94, opened at $1.91.
- Volume was 472.20K shares, 0.8x its 50-day average of 597.05K.
- Price is -4.5% vs its 50-day average ($1.98) and -16.7% vs its 200-day average ($2.27).
- 52-week range $1.60–$4.94; today's close sits at 9% of that range, 61.7% below the 52-week high.
BDTX latest news & SEC filings
Every SEC filing by or about BDTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Behbahani Ali received an award of 7,707 shares at $1.93 (≈$14.87K) on Sep 18, 2026; now holds 110,236
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Raman Prakash received an award of 6,801 shares at $1.93 (≈$13.13K) on Sep 18, 2026; now holds 51,840
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$9.90M (prior year -$10.56M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.17 (prior year -$0.19) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade BDTX
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 16, 2026, Dec 3, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.02% (largest 7.2%).
- Liquidity: about 638.07K shares (≈$1.10M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.72 vs a range of $1.60–$4.94 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 29, 2026.
- Share count: 57.45M shares outstanding (Jul 30, 2026), +0.9% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
BDTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.75 | 1.75 | 1.67 | 1.72 | 539.75K |
| Oct 15, 2026 | 1.69 | 1.74 | 1.67 | 1.74 | 624.70K |
| Oct 14, 2026 | 1.67 | 1.76 | 1.63 | 1.70 | 1.07M |
| Oct 13, 2026 | 1.76 | 1.77 | 1.60 | 1.68 | 1.14M |
| Oct 12, 2026 | 1.87 | 1.87 | 1.76 | 1.77 | 377.70K |
| Oct 9, 2026 | 1.81 | 1.83 | 1.79 | 1.83 | 448.80K |
| Oct 8, 2026 | 1.81 | 1.81 | 1.77 | 1.81 | 785.00K |
| Oct 7, 2026 | 1.79 | 1.87 | 1.77 | 1.83 | 563.30K |
| Oct 6, 2026 | 1.94 | 1.96 | 1.79 | 1.80 | 839.10K |
| Oct 5, 2026 | 1.90 | 1.95 | 1.88 | 1.94 | 838.60K |
| Oct 2, 2026 | 1.91 | 1.94 | 1.88 | 1.89 | 472.20K |
| Oct 1, 2026 | 1.88 | 1.90 | 1.84 | 1.88 | 399.10K |
| Sep 30, 2026 | 1.89 | 1.93 | 1.85 | 1.88 | 551.80K |
| Sep 29, 2026 | 1.84 | 1.89 | 1.83 | 1.87 | 440.20K |
| Sep 28, 2026 | 1.89 | 1.89 | 1.81 | 1.83 | 648.30K |
| Sep 25, 2026 | 1.91 | 1.91 | 1.85 | 1.88 | 378.30K |
| Sep 24, 2026 | 1.90 | 1.91 | 1.83 | 1.89 | 459.70K |
| Sep 23, 2026 | 1.97 | 1.97 | 1.85 | 1.90 | 613.50K |
| Sep 22, 2026 | 1.93 | 2.00 | 1.90 | 1.98 | 743.90K |
| Sep 21, 2026 | 1.96 | 1.97 | 1.91 | 1.95 | 827.10K |
About Black Diamond Therapeutics
Black Diamond Therapeutics (BDTX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. Fiscal year ends December 31. SEC CIK 1701541.
BDTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ali Behbahani | Director | Sep 21, 2026 |
| Shannon Campbell | Director | Jun 29, 2026 |
| Kapil Dhingra | Director | Jun 29, 2026 |
| Samarth Kulkarni | Director | Jun 29, 2026 |
| Garry E Menzel | Director | Jun 29, 2026 |
| Prakash Raman | Director | Sep 21, 2026 |
| Mark A. Velleca | PRESIDENT & CEO | Jan 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | Jan 23, 2026 |
| Brent Hatzis-Schoch | SEE REMARKS | Jan 23, 2026 |
| Erika Jones | SEE REMARKS | Jan 23, 2026 |
| Mark A. Velleca | PRESIDENT & CEO | Jan 23, 2026 |
| Sergey Yurasov | CHIEF MEDICAL OFFICER | Jan 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
BDTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $22.37M | 0.39 | $29.61M |
| Dec 31, 2024 | — | $-69.68M | -1.27 | $-62.30M |
| Dec 31, 2023 | — | $-82.44M | -1.88 | $-66.72M |
| Dec 31, 2022 | — | $-91.17M | -2.52 | $-85.08M |
| Dec 31, 2021 | — | $-125.60M | -3.47 | $-100.15M |
Latest balance sheet: total assets $125.03M, total liabilities $28.94M, cash $19.19M (as of Jun 30, 2026).
BDTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $1.79 |
| May 7, 2026 | 8-K Item 2.02 (results) | $2.72 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $2.19 |
| Dec 3, 2025 | 8-K Item 2.02 (results) | $2.69 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $3.98 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $2.28 |
| May 12, 2025 | 8-K Item 2.02 (results) | $1.75 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $1.90 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $3.25 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 12, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BDTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.